Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers.
Susanne ProthonUlrika Wählby HamrénUlrika TehlerEsther YoonHenrik ForsmanCecilia ArfvidssonAjay AggarwalYingxue ChenPublished in: Drug design, development and therapy (2019)
In conclusion, the early clinical evaluation of inhaled AZD7594 suggests that this novel SGRM is well tolerated in the dose range investigated and also in a Japanese population. It shows dose-proportional plasma exposure, moderate accumulation and has limited impact on systemic markers of glucocorticoid activity.